Step 1 topics → Hematology and Oncology → Transfusion Reactions

Transfusion Reactions

USMLE Step 1 trap: Misclassifies acute hemolytic transfusion reaction as type I rather than type II hypersensitivity. Acute hemolytic transfusion reaction is a type II hypersensitivity reaction mediated by preformed IgM anti-A or anti-B antibodies activating complement.

Transfusion reactions are a favorite USMLE Step 1 topic because they require you to integrate immunology, pulmonology, and clinical reasoning all at once. The exam doesn't just ask you to name a reaction — it gives you a vignette mid-transfusion and asks you to identify the mechanism, the hypersensitivity type, and the correct management step. You need to distinguish six or more distinct reaction types that can look superficially similar (fever, hypotension, respiratory distress) but have completely different pathophysiology and treatments.

What makes this topic hard is that the clinical presentations overlap. Fever appears in acute hemolytic reactions, FNHTR, and bacterial contamination. Respiratory distress appears in both TRALI and TACO. Students who memorize lists of symptoms without anchoring them to mechanism will get these questions wrong. The exam specifically rewards students who understand WHY each reaction happens — the antibody class involved, the complement pathway triggered, or the hemodynamic profile — because those mechanistic details are what distinguish the answer choices.

The highest-yield misconceptions involve misclassifying the hypersensitivity type of acute hemolytic reactions (it's type II, not type I), confusing the prevention strategies for FNHTR versus transfusion-associated GVHD, and failing to distinguish TRALI from TACO based on cardiogenic versus noncardiogenic physiology. USMLE Step 1 loves to test whether you know that irradiation — not leukoreduction — prevents TA-GVHD, and whether you recognize IgA deficiency as the setup for anaphylactic transfusion reactions.

From real student decks
49%have cards covering this topic
35%have mature cards

Common misconceptions

Common mistake
Wrong: Acute hemolytic transfusion reaction is a type I (IgE-mediated) hypersensitivity reaction.
Right: Acute hemolytic transfusion reaction is a type II hypersensitivity reaction mediated by preformed IgM anti-A or anti-B antibodies activating complement.
Acute hemolytic transfusion reaction is type II hypersensitivity, not type I. Type I (anaphylactic) is IgE-mediated and involves mast cell degranulation. In acute hemolytic reactions, preformed IgM anti-A or anti-B antibodies bind to ABO antigens on transfused RBCs and activate the classical complement cascade, leading to intravascular hemolysis — the defining feature of type II cytotoxic hypersensitivity. The clinical consequences (hemoglobinuria, renal failure, DIC) all follow from complement-mediated RBC destruction, not mast cell release.
Common mistake
Wrong: Febrile non-hemolytic transfusion reaction (FNHTR) is caused by bacterial contamination of the blood product.
Right: FNHTR is caused by recipient antibodies against donor leukocyte antigens (HLA) or by cytokines accumulated in stored blood; it is prevented by leukoreduction.
FNHTR is not caused by bacterial contamination — that's a separate entity (septic transfusion reaction) with more severe systemic signs. FNHTR occurs because the recipient has antibodies directed against donor leukocyte antigens (HLA antigens), or because cytokines (IL-1, IL-6, TNF) have accumulated in the stored blood product over time and trigger fever when infused. Because leukocytes are the source of both the antigenic target and cytokine production, leukoreduction prevents FNHTR. Bacterial contamination would require cultures and antibiotics — a completely different workup.
Common mistake
Gap: Missing that transfusion anaphylaxis is specifically associated with IgA deficiency and anti-IgA antibodies
Anaphylactic transfusion reactions occur in IgA-deficient patients who have anti-IgA antibodies; prevention requires IgA-deficient or washed blood products.
Anaphylactic transfusion reactions most classically occur in patients with selective IgA deficiency who have developed anti-IgA IgE antibodies, usually from prior transfusion or pregnancy exposure. When they receive a standard blood product containing IgA, those anti-IgA antibodies trigger systemic mast cell degranulation. This is why the management is different from a simple urticarial reaction: these patients require washed blood products (to remove plasma IgA) or products from IgA-deficient donors. Failing to screen for IgA deficiency in a patient with a prior anaphylactic transfusion reaction is a testable error.
Common mistake
Wrong: TRALI and TACO are distinguished primarily by the presence or absence of fever.
Right: TRALI is noncardiogenic pulmonary edema (low/normal PCWP, anti-HLA antibodies from donor) occurring within 6 hours, while TACO is cardiogenic fluid overload (elevated BNP, elevated PCWP) responding to diuresis.
Fever is not the distinguishing feature between TRALI and TACO — both can present with fever, hypoxia, and bilateral infiltrates on chest X-ray. The critical distinction is hemodynamic. TRALI is noncardiogenic: it results from donor anti-HLA or anti-neutrophil antibodies activating neutrophils in the pulmonary vasculature, causing capillary leak with a normal or low pulmonary capillary wedge pressure. TACO is cardiogenic fluid overload: elevated BNP, elevated PCWP, and it responds to diuresis. Treatment diverges sharply — TRALI is managed with supportive care (no diuretics), while TACO requires diuresis.
Common mistake
Wrong: Transfusion-associated GVHD is prevented by leukoreduction filters.
Right: Transfusion-associated GVHD is prevented by irradiation of blood products, which inactivates donor T lymphocytes; leukoreduction alone is insufficient.
Leukoreduction reduces the number of donor leukocytes but does not reliably eliminate all T lymphocytes, and the residual T cells are still capable of engrafting in an immunocompromised host and attacking recipient tissues. Irradiation inactivates donor T lymphocyte DNA, rendering them unable to proliferate — that's what actually prevents TA-GVHD. The distinction matters clinically and on USMLE Step 1: immunocompromised patients (severe combined immunodeficiency, Hodgkin lymphoma patients, bone marrow transplant recipients) and directed donations from relatives must receive irradiated products, not just leukoreduced ones.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a patient with ABO-incompatible blood, identify acute hemolytic transfusion reaction as type II hypersensitivity driven by preformed IgM antibodies activating complement, and select the correct immediate management (stop transfusion, IV fluids, monitor urine output).
  2. Distinguish febrile non-hemolytic transfusion reaction from bacterial contamination: FNHTR is caused by recipient anti-leukocyte (anti-HLA) antibodies or cytokines in stored blood, is not infectious, and is prevented by leukoreduction — not antibiotics.
  3. Identify the correct prevention and mechanism for urticarial reactions (preformed IgE against donor plasma proteins, treated with antihistamines, transfusion can continue) versus anaphylactic reactions in IgA-deficient patients with anti-IgA IgE antibodies (requires IgA-deficient or washed products).
  4. Differentiate TRALI from TACO using hemodynamic profile: TRALI is noncardiogenic pulmonary edema with normal or low pulmonary capillary wedge pressure and anti-HLA donor antibodies; TACO is cardiogenic fluid overload with elevated BNP and PCWP that responds to diuretics.
  5. Identify that transfusion-associated GVHD is prevented specifically by irradiation of blood products (to inactivate donor T lymphocytes), and that leukoreduction alone is insufficient — a distinction the exam tests directly in immunocompromised patient scenarios.
  6. Recognize delayed hemolytic transfusion reaction as caused by an anamnestic IgG antibody response against minor blood group antigens (e.g., Kidd, Duffy), presenting days after transfusion with a positive direct Coombs test and extravascular hemolysis.

Can you avoid these mistakes?

A patient receives their second unit of pRBCs. Thirty minutes into the transfusion, they develop fever, flank pain, and dark urine. The transfusion is stopped. What hypersensitivity type is this, what antibody class is responsible, and what are the two most critical management priorities?
A patient with a history of recurrent sinopulmonary infections develops urticaria, bronchospasm, and hypotension within minutes of starting a plasma transfusion. IgG levels are normal. What underlying condition makes this patient uniquely susceptible, what antibody is responsible for the reaction, and what must be done differently for future transfusions?
Two post-transfusion patients both develop bilateral pulmonary infiltrates and hypoxia within 6 hours of completing a transfusion. Patient A has an elevated BNP, elevated PCWP, and improves with furosemide. Patient B has a normal PCWP and does not improve with furosemide. Identify each diagnosis, state the mechanism of the noncardiogenic case, and explain why diuretics are inappropriate for Patient B.
A patient with acute leukemia undergoing induction chemotherapy is about to receive a directed blood donation from their sibling. What complication is this patient specifically at risk for, why is standard leukoreduction insufficient to prevent it, and what must be done to the blood product before transfusion?

Related topics

Blood Products and ABO Compatibility Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →